Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO).
about
Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemiaBendamustine for patients with B cell lymphoid malignanciesPurine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignanciesBendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment GroupEvaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma.The role of bendamustine in the treatment of indolent non-Hodgkin lymphomaBendamustine: safety and efficacy in the management of indolent non-hodgkins lymphomaBendamustine for treatment of chronic lymphocytic leukemiaRelapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease.Bendamustine as a model for the activity of alkylating agents.Bendamustine (treanda) for chronic lymphocytic leukemia: a brief overviewBendamustine in the treatment of non-Hodgkin's lymphomas.Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.Bendamustine: role and evidence in lymphoma therapy, an overview.Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options.Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin's lymphoma.Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma.
P2860
Q24200280-5CAF4BF0-7722-4606-BE33-AEB056D5B86FQ24236426-D6C0F86A-FF84-4E2E-B19C-6A20C49224D3Q28540830-4465EDD0-1C9D-4402-87C0-663DCE7F11CCQ30435188-435B3202-8148-45F6-AC91-4BC8C68D5A63Q33379949-CA24447D-0536-44C4-A6E8-3A07DDBAAEB0Q33749652-768D49AD-2E41-40A7-AFAD-443E1C19FB24Q34129360-15C63492-6B57-48A5-A27D-FAF2B2149342Q34418442-89B7F0FD-1318-4FA6-9D4B-29D19BA07ABDQ35052538-D1C28A59-4148-4EFD-A000-9F88E0C6F3CCQ36305762-E401B1B1-0F27-4410-86C1-538BE7D3DC7FQ36411719-032B298A-124C-45B3-8461-31D5F5270424Q37179377-BA8D5449-1C69-456D-91EE-EDA02B8862C5Q37229148-F8747003-34A7-4D9F-8E87-382A2AD75115Q37771253-312B0B9E-5E6D-4231-990C-B0BE45552A3DQ37788236-4BAB4945-5A38-4347-8E50-04FA7CEC931CQ38158084-6922054F-82E6-404E-8113-59D97D36878CQ38594531-9FA0C7A3-21F7-4278-B974-3885753179D9Q43203237-D9C58300-8AB4-4722-BC03-BBAFF02A5A95Q43254054-3C016092-1A9E-45A6-9576-6512F5C4A099
P2860
Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO).
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Fludarabine and bendamustine i ...... ematology and oncology (OSHO).
@ast
Fludarabine and bendamustine i ...... ematology and oncology (OSHO).
@en
type
label
Fludarabine and bendamustine i ...... ematology and oncology (OSHO).
@ast
Fludarabine and bendamustine i ...... ematology and oncology (OSHO).
@en
prefLabel
Fludarabine and bendamustine i ...... ematology and oncology (OSHO).
@ast
Fludarabine and bendamustine i ...... ematology and oncology (OSHO).
@en
P2093
P2860
P921
P1433
P1476
Fludarabine and bendamustine i ...... ematology and oncology (OSHO).
@en
P2093
Astrid Franke
Christoph Kahl
Gerd Müller
Henning Eschenburg
Kathleen Jentsch-Ullrich
Martin Mohren
Michael Assmann
Michael Herold
Michael Koenigsmann
Rainer Bartsch
P2860
P304
P356
10.1080/1042819042000223822
P577
2004-09-01T00:00:00Z